Michael Szarek

List of Publications by Year
in descending order

106 papers	15,663 citations	61984 43 h-index	36028 97 g-index
117 all docs	117 docs citations	117 times ranked	13976 citing authors

#	Article	IF	Citations
1	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	1.8	18
2	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American Heart Journal, 2022, 246, 136-143.	2.7	8
3	Topical Calcipotriol Plus 5-Fluorouracil Immunotherapy for Actinic Keratosis Treatment. JID Innovations, 2022, 2, 100104.	2.4	2
4	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	3.8	3
5	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. American Journal of Medicine, 2022, , .	1.5	0
6	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 330-340.	11.4	19
7	Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal, 2022, 43, 1554-1565.	2.2	23
8	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation Genomic and Precision Medicine, 2022, 15, 101161CIRCGEN121003503.	3.6	3
9	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, .	3.7	4
10	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	1.7	4
11	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. European Journal of Preventive Cardiology, 2022, 29, 1842-1851.	1.8	7
12	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580.	5.9	11
13	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 2021, 28, 33-43.	1.8	33
14	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
15	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
16	Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.. Journal of Clinical Oncology, 2021, 39, 298-298.	1.6	1
17	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
18	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation, 2021, 143, 1109-1122.	1.6	46

#	Article	IF	Citations
19	METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL. Journal of the American College of Cardiology, 2021, 77, 150.	2.8	0
20	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PADÂTrial. Journal of the American College of Cardiology, 2021, 78, 317-326.	2.8	30
21	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	3.9	32
22	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. Journal of the American College of Cardiology, 2021, 78, 757-759.	2.8	2
23	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European Heart Journal, 2021, 42, 4040-4048.	2.2	13
24	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	2.8	58
25	Efficacy of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease With Venous and Prosthetic Surgical Bypass Conduits: Insights from the VOYAGER PAD Trial. Journal of Vascular Surgery, 2021, 74, e24-e25.	1.1	1
26	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer, 2021, 19, 468.e1-468.e5.	1.9	7
27	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 144, 1831-1841.	1.6	19
28	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Science Advances, 2021, 7, eabi7511.	10.3	23
29	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation, 2020, 141, 624-636.	1.6	155
30	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
31	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal, 2020, 41, 2248-2258.	2.2	51
32	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	2.2	117
33	Reply. Journal of the American College of Cardiology, 2020, 76, 886-888.	2.8	2
34	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal, 2020, 41, 4114-4123.	2.2	35
35	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 75, 2297-2308.	2.8	48
36	Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories. Journal of the American College of Cardiology, 2020, 75, 2110-2118.	2.8	27

#	Article	IF	Citations
37	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96
38	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. Circulation, 2020, 141, 1608-1617.	1.6	104
39	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEYÂOUTCOMES. Journal of the American College of Cardiology, 2020, 75, 448-451.	2.8	6
40	Response by Schwartz et al to Letter Regarding Article, â€œPeripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trialâ€. Circulation, 2020, 142, e335-e336.	1.6	1
41	Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors. , 2020, , .		0
42	Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial. Circulation, 2020, 142, .	1.6	0
43	Abstract 14328: Relation of Lipoprotein(a) Levels to Incident Diabetes and Modification by Alirocumab Treatment: An Analysis of the Odyssey Outcomes Trial. Circulation, 2020, 142, .	1.6	0
44	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
45	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trialâ€. Journal of Clinical Lipidology, 2019, 13, e54-e55.	1.5	0
46	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
47	REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL. Journal of the American College of Cardiology, 2019, 73, 4.	2.8	1
48	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
49	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 2019, 140, 2054-2062.	1.6	83
50	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
51	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
52	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
53	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
54	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2019, 73, 2034.	2.8	0

#	Article	IF	Citations
55	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
56	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell, 2018, 172, 825-840.e18.	28.9	312
57	A Phase 1 Trial of CNDO-109â€“Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1581-1589.	2.0	50
58	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
59	Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.. Journal of Clinical Oncology, 2018, 36, 3095-3095.	1.6	10
60	Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetesâ€”Prespecified Analyses of ODYSSEY OUTCOMES. Diabetes, 2018, 67, .	0.6	12
61	Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies. , 2018, , .		1
62	Early, intensive statin treatment reduces â€˜hardâ€™ cardiovascular outcomes after acute coronary syndrome. European Journal of Preventive Cardiology, 2017, 24, 1294-1296.	1.8	30
63	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. Journal of the American College of Cardiology, 2017, 69, 153.	2.8	2
64	Rapidly Improving Stroke Symptoms: A Pilot, Prospective Study. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1211-1216.	1.6	2
65	Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3795-3795.	1.4	15
66	Factors Related to the Sensitivity of Emergency Medical Service Impression of Stroke. Prehospital Emergency Care, 2014, 18, 387-392.	1.8	33
67	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. American Heart Journal, 2014, 168, 682-689.e1.	2.7	365
68	The Correlation between Global Health Experiences in Low-Income Countries on Choice of Primary Care Residencies for Graduates of an Urban US Medical School. Journal of Urban Health, 2014, 91, 394-402.	3.6	19
69	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood, 2014, 124, 385-392.	1.4	195
70	Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. Blood, 2014, 124, 2320-2320.	1.4	5
71	Abstract W P62: Rapidly Improving Stroke Symptoms (RISS): A Prospective, Pilot Study. Stroke, 2014, 45, .	2.0	0
72	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	1.4	7

#	Article	IF	Citations
73	Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.. Journal of Clinical Oncology, 2013, 31, 7029-7029.	1.6	19
74	Maximum carotid artery wall thickness and risk factors in a young primary prevention population. Brain and Behavior, 2012, 2, 590-594.	2.2	0
75	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. Blood, 2012, 120, 3625-3625.	1.4	10
76	Dabigatran for stroke prevention in patients with atrial fibrillation and previous stroke or transient ischemic attack: does dose matter?. Future Neurology, 2011, 6, 155-158.	0.5	0
77	Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Cardiology, 2010, 106, 354-359.	1.6	35
78	Estimation of overall survival in an â€˜illnessâ€“deathâ€™ model with application to the vertical transmission of HIVâ€•. Statistics in Medicine, 2010, 29, 2045-2054.	1.6	6
79	Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 315-320.	2.8	19
80	Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clinical Chemistry, 2009, 55, 473-480.	3.2	78
81	Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus â‰¥65 Years With Coronary Heart Disease (from the Incremental DEcrease through) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	50
82	Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2009, 52, 218-225.	6.3	35
83	Nonparametric Estimation in a Markov â€œIllnessâ€“Deathâ€•Process from Interval Censored Observations with Missing Intermediate Transition Status. Biometrics, 2009, 65, 143-151.	1.4	33
84	Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 2186-2196.	2.8	91
85	Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy. Journal of the American College of Cardiology, 2009, 54, 2353-2357.	2.8	59
86	Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology, 2008, 70, 2364-2370.	1.1	372
87	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research, 2008, 5, 177-183.	2.0	44
88	Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 142-147.	2.4	65
89	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	1.6	405
90	Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. Stroke, 2007, 38, 3198-3204.	2.0	302

#	Article	IF	Citations
91	HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine, 2007, 357, 1301-1310.	27.0	1,390
92	204. Journal of Clinical Lipidology, 2007, 1, 156-157.	1.5	0
93	Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Medicine, 2007, 24, 1313-1321.	2.3	37
94	Effects of High-Dose Atorvastatin in Patients â‰¥65 Years of Age With Acute Coronary Syndrome (from) Tj ETQq0 0 0 rgBT /Overlock 1 Journal of Cardiology, 2007, 99, 632-635.	1.6	56
95	Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. American Journal of Cardiology, 2006, 97, 61-67.	1.6	203
96	Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: A potential marker of response to immunotherapy?. International Journal of Cancer, 2006, 119, 157-161.	5.1	11
97	High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2006, 355, 549-559.	27.0	2,497
98	Presence and Prognostic Significance of Melanoma-Associated Antigens CYT-MAA and HMW-MAA in Serum of Patients with Melanoma. Journal of Investigative Dermatology, 2005, 125, 526-531.	0.7	32
99	Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care, 2005, 28, 2508-2513.	8.6	67
100	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. European Heart Journal, 2005, 26, 890-896.	2.2	187
101	High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 294, 2437.	7.4	1,401
102	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. Circulation, 2004, 110, 1406-1412.	1.6	209
103	Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation, 2004, 110, 386-391.	1.6	163
104	Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. American Journal of Cardiology, 2003, 92, 670-676.	1.6	164
105	High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. Circulation, 2003, 108, 1560-1566.	1.6	383
106	VALIDATION OF A BRIEF SCREENING MEASURE OF ENVIRONMENTAL CHEMICAL SENSITIVITY: THE CHEMICAL ODOR INTOLERANCE INDEX. Journal of Environmental Psychology, 1997, 17, 345-351.	5.1	56